- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02772926
Benfotiamine Effect on Advanced Glycation End Products(AGEs) and Soluble Receptor for AGEs(sRAGE) in Diabetes Mellitus.
Benfotiamine Effect on Advanced Glycation End Products(AGEs) and Soluble Receptors for AGEs(sRAGE) in Type 2 Diabetes Mellitus.
Several mechanisms have been implicated in the pathophysiology of the complications of diabetes mellitus (DM), one of them is the formation and accumulation of a heterogeneous group of compounds called advanced glycation end products (AGEs). The interaction of these compounds with their receptor, the receptor for advanced glycation end products (RAGE) triggers several signalling pathways which will lead to increase in inflammatory molecules and enhanced reactive oxygen species. In addition, to the membrane receptor RAGE, there are two soluble forms, the soluble RAGE (sRAGE) and the endogenous secretory RAGE (esRAGE), these soluble receptors are capable to bind AGEs and block the AGE-RAGE axis. It has been observed that in diabetes the needs of thiamine are increased, and it could be an inhibition of the pentose phosphate pathway (thiamine is an essential cofactor in this pathway) and activation of other metabolic pathways among them AGEs formation. It has been proposed that supplementation of benfotiamine could decreased the risk of micro and macrovascular complications, and this could be in part because a decreased in the formation of AGEs. For this reason, the objective of this study was to evaluate the effect of benfotiamine on AGEs and its soluble receptors (sRAGE) in patients with type 2 diabetes.
The specific objectives in the current study are:
- To evaluate and compare clinical and anthropometric characteristics in type 2 DM patients with and without benfotiamine treatment.
- To evaluate and compare in type 2 DM patients with and without benfotiamine treatment the following biochemical parameters: total AGEs, Carboxymethyl-lysine (CML), sRAGE, glucose, hemoglobin A1c, lipids (total cholesterol, C-HDL, C-LDL, and triglycerides).
- To evaluate and compare dietary data such as dietary AGEs and macro and macronutrients in type 2 DM patients with and without benfotiamine treatment.
Type of study: This is a randomized, controlled, double-blind clinical trial
Methods 34 patients will be recruited, 17 per group. After signing the inform consent subjects will be assessed for inclusion criteria. Subjects meeting the inclusion criteria and those whom accept to participate will be randomized to receive either a placebo or benfotiamine treatment for 12 weeks.
At the end of the 12 weeks all the basal assessments will be repeated.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetes mellitus (DM) and its related complications are an increasing health burden all over the world. Insulin deficiency or the insulin resistance in patients with diabetes triggers hyperglycemia which is the main responsible for the micro and macrovascular complications. Several mechanisms have been implicated in the pathophysiology of these complications, one of them is the formation and accumulation of a heterogeneous group of compounds called advanced glycation end products (AGEs). The interaction of these compounds with their receptor, the receptor for advanced glycation end products (RAGE) triggers several signalling pathways which will lead to increase in inflammatory molecules and enhanced reactive oxygen species. In addition, to the membrane receptor RAGE, there are two soluble forms, the soluble RAGE (sRAGE) and the endogenous secretory RAGE (esRAGE), these soluble receptors are capable to bind AGEs and block the AGE-RAGE axis. It has been observed that in diabetes the needs of thiamine are increased, and it could be an inhibition of the pentose phosphate pathway (thiamine is an essential cofactor in this pathway) and activation of other metabolic pathways among them AGEs formation.
It has been proposed that supplementation of benfotiamine could decreased the risk of micro and macrovascular complications, here we proposed that this could be because a decreased in the formation of AGEs. For this reason, the objective of this study was to evaluate the effect of benfotiamine on AGEs and its soluble receptors (sRAGE) in patients with type 2 diabetes.
The specific objectives in the current study are:
- To evaluate and compare clinical and anthropometric characteristics in type 2 DM patients with and without benfotiamine treatment.
- To evaluate and compare in type 2 DM patients with and without benfotiamine treatment the following biochemical parameters: Carboxymethyl-lysine (CML)(a marker for AGEs levels), sRAGE, glucose, hemoglobin A1c, lipids (total cholesterol, C-HDL, C-LDL, and triglycerides).
- To evaluate and compare dietary data such as dietary AGEs and macro and macronutrients in type 2 DM patients with and without benfotiamine treatment.
Type of study: This is a randomized, controlled, double-blind clinical trial
Methods 34 patients will be recruited, 17 per group, level of significance is 0.05 and power 80%. Size was calculated by difference in group means divided by standard deviation.
After signing the inform consent subjects will be assessed for inclusion criteria. Subjects meeting the inclusion criteria and those whom accept to participate will be randomly assigned to receive either a placebo or benfotiamine treatment for 12 weeks. The randomization will be done with a statistical Software (SPSS, V. 21, Chicago).
After group assignment, subjects will be instructed to assist to the Research Center three times for initial assessments.
During the first visit the subject will answer a questionnaire with personal data, medical history and current medications. Patients will be asked to have 10-12 hours of fasting for the blood sample and for the body composition assessment, weight, height and waist circumference will be measured too. Also the blood pressure will be measured during this first visit.
For the dietary assessment 24-hour dietary recalls will be applied in 3 different days. Subjects will be instructed not to change their dietary habits and to maintain their exercise levels during the length of the study.
Subject will visit the Research Center every two-weeks to receive a new bottle of pills and to answer an adherence questionnaire and also to ask for possible adverse events.
At week six in addition to the adherence questionnaire another blood sample and blood pressure will be taken. In addition, another 24-hour dietary recall will be completed
At the end of the 12 weeks all the basal assessments will be repeated.
Main study parameters/ endpoints Change from basal serum levels of the following parameters: measured basal and at the end of study: Carboxymethyl-lysine (CML), and sRAGE
Serum samples will be stored frozen at -80°C until assessment.
- Identification and quantification of CML will be measured with an immunoassay commercial kit (OxiSelect ™)
- Identification and quantification of sRAGE will be measured with Human RAGE Immunoassay commercial kit (Quantikine®)
Statistical analysis
Data will be presented as mean and standard deviation if presents normal distribution. Normality of data will be evaluated by Kolmogorov-Smirnov. To determinate basal differences between groups a t-Student test for independent samples will be applied. For the difference between groups before and after treatment a t-Student test for dependent samples will be applied. If data have not normal distribution, no parametrical tests will be used.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guanajuato
-
León, Guanajuato, Mexico, 37320
- Department of Medical Sciences, University of Guanajuato, León Mexico
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with type 2 diabetes:
- With no complications
- Not taking insulin
- With 5 years since diagnosis
- Not taking any vitamins
- Not pregnant or lactating women
- Not smoking
Exclusion Criteria:
- Intolerance to the benfotiamine treatment
- Lack of adherence (taking less than 80% of the pills)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
450 g per pill, 2 pills per day to get 900 mg per day
|
Placebo 900 mg per day
|
Active Comparator: Benfotiamine
Benfotiamine (S-Benzoylthiamine O-monophosphate) 450 mg per pill, 2 pills per day to get 900 mg per day
|
Benfotiamine (S-Benzoylthiamine O-monophosphate) 900 mg per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum levels of Carboxymethyl-lysine
Time Frame: 12 weeks
|
Changes in serum levels of Carboxymethyl-lysine, a marker of AGEs, will be measured.
Carboxymethyl-lysine serum levels will be measured by immunoassay and the units reported will be in milligrams per deciliter.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ma. Eugenia Garay-Sevilla, MD, Universidad de Guanajuato
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIBIUG-P-27-2015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaNot yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States